je.st
news
Tag: designation
Alexion's Soliris (eculizumab) Receives Orphan Drug Designation For The Treatment Of Neuromyelitis Optica (NMO)
2013-06-27 18:50:00| drugdiscoveryonline News Articles
Alexion Pharmaceuticals, Inc. recently announced that Soliris (eculizumab), the company’s first-in-class terminal complement inhibitor, has been granted an orphan drug designation by the U.S. Food and Drug Administration (FDA) for the treatment of neuromyelitis optica (NMO), a life-threatening, ultra-rare neurological disorder
Tags: treatment
drug
receives
designation
Gilead Announces U.S. FDA Priority Review Designation for Sofosbuvir for the Treatment of Hepatitis C
2013-06-09 00:00:05| Biotech - Topix.net
Gilead Sciences, Inc. today announced that the U.S. Food and Drug Administration has granted priority review to the company's New Drug Application for sofosbuvir, a once-daily oral nucleotide analogue inhibitor for the treatment of chronic hepatitis C virus infection.
Tags: of
review
treatment
priority
Negligible BSE Risk Designation: What Are the Benefits?
2013-06-06 22:41:00| Beef
By Joe Schuele, USMEF The OIEs negligible risk designation creates an opportunity for the U.S. to reengage its trading partners on removal of the remaining restrictions on beef imports from the U.S. read more
Tags: risk
benefits
designation
negligible
Precision Metal Industries Recieves Preferred Supplier Designation from Lockheed Martin
2013-05-09 06:00:00| Industrial Newsroom - All News for Today
Precision Metal Industries (PMI), an innovative precision sheet metal fabrication company dedicated to offering quality results and unmatched customer service, has today announced that it has earned approval in the Lockheed Martin Missiles and Fire Control Preferred Supplier Program. With this prestigious designation from Lockheed Martin, PMI joins just 74 other companies that have achieved this level of supplier status. This recognition reflects excellence in quality, consistent and on-time ...
Tags: martin
metal
preferred
industries
Merck Announces Breakthrough Therapy Designation for Lambrolizumab an Investigational Antibody Therapy for Advanced Melanoma
2013-04-24 13:30:00| Merck.com - Research & Development News
Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has designated lambrolizumab (MK-3475) as a Breakthrough Therapy for the treatment of patients with advanced melanoma. Lambrolizumab is Mercks investigational antibody therapy targeting Programmed Death receptor (PD-1) that is currently being evaluated for the treatment of patients with advanced melanoma, and other tumor types. Language: English Contact HTML: MerckMedia:Caroline Lapppetito, 267-305-7639orInvestors:Carol Ferguson, 908-423-4465orJustin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: advanced
therapy
announces
designation
Sites : [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] next »